Liver fat accumulation assessed by computed tomography is an independent risk factor for diabetes mellitus in a population-based study: SESSA (Shiga Epidemiological Study of Subclinical Atherosclerosis).

[1] Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Current diabetes reports. 2010;10:306-15.

[2] Kadowaki S, Tamura Y, Someya Y, Takeno K, Kaga H, Sugimoto D, et al. Fatty Liver Has Stronger Association With Insulin Resistance Than Visceral Fat Accumulation in Nonobese Japanese Men. Journal of the Endocrine Society. 2019;3:1409-16.

[3] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md). 2016;64:73-84.

[4] Kadowaki S, Miura K, Kadowaki T, Fujiyoshi A, El-Saed A, Masaki KH, et al. International Comparison of Abdominal Fat Distribution Among Four Populations: The ERA-JUMP Study. Metabolic syndrome and related disorders. 2018;16:166-73.

[5] Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N. Obesity and type 2 diabetes in Japanese patients. Lancet (London, England). 2003;361:85.

[6] Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. The American journal of gastroenterology. 2013;108:1861-8.

[7] Chen GY, Cao HX, Li F, Cai XB, Ao QH, Gao Y, et al. New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel Cohort. Journal of diabetes investigation. 2016;7:206-11.

[8] Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes care. 2007;30:2940-4.

[9] Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. Journal of hepatology. 1997;27:108-13.

[10] Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230:276-80.

[11] Shah RV, Allison MA, Lima JA, Bluemke DA, Abbasi SA, Ouyang P, et al. Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;242:211-7.

[12] Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bidirectional analysis between fatty liver and cardiovascular disease risk factors. Journal of hepatology. 2017;66:390-7.

[13] Hisamatsu T, Miura K, Arima H, Kadota A, Kadowaki S, Torii S, et al. Smoking, Smoking Cessation, and Measures of Subclinical Atherosclerosis in Multiple Vascular Beds in Japanese Men. Journal of the American Heart Association. 2016;5.

[14] Fujiyoshi A, Miura K, Kadowaki S, Azuma K, Tanaka S, Hisamatsu T, et al. Lifetime cigarette smoking is associated with abdominal obesity in a community-based sample of Japanese men: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). Preventive medicine reports. 2016;4:225-32.

[15] Nakamura M, Sato S, Shimamoto T. Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. Journal of atherosclerosis and thrombosis. 2003;10:145-53.

[16] Takagi Y. [Standardization of laboratory data: verification of inter-laboratory data variations]. Rinsho byori The Japanese journal of clinical pathology. 2006;54:947-59.

[17] Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of diabetes investigation. 2012;3:39-40.

[18] Azuma K, Kadowaki T, Cetinel C, Kadota A, El-Saed A, Kadowaki S, et al. Higher liver fat content among Japanese in Japan compared with non-Hispanic whites in the United States. Metabolism: clinical and experimental. 2009;58:1200-7.

[19] Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 1980;137:727-9.

[20] Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, et al. Comparison of CT methods for determining the fat content of the liver. AJR American journal of roentgenology. 2007;188:1307-12.

[21] Kawata R, Sakata K, Kunieda T, Saji S, Doi H, Nozawa Y. Quantitative evaluation of fatty liver by computed tomography in rabbits. AJR American journal of roentgenology. 1984;142:741-6.

[22] Bydder GM, Chapman RW, Harry D, Bassan L, Sherlock S, Kreel L. Computed tomography attenuation values in fatty liver. The Journal of computed tomography. 1981;5:33-5.

[23] New criteria for 'obesity disease' in Japan. Circulation journal : official journal of the Japanese Circulation Society. 2002;66:987-92.

[24] Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, et al. Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of gastroenterology. 2015;50:364-77.

[25] EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. Journal of hepatology. 2016;64:1388-402.

[26] Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. European radiology. 2011;21:87-97.

[27] Yamazaki H, Tsuboya T, Katanuma A, Kodama Y, Tauchi S, Dohke M, et al. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study. Diabetes care. 2016;39:1677-83.

[28] Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes care. 2015;38:1673-9.

[29] Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 2014;34:1155-61.

[30] Kato K, Takamura T, Takeshita Y, Ryu Y, Misu H, Ota T, et al. Ectopic fat accumulation and distant organ-specific insulin resistance in Japanese people with nonalcoholic fatty liver disease. PloS one. 2014;9:e92170.

[31] Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. The Journal of clinical endocrinology and metabolism. 2013;98:483-95.

[32] Everhart JE, Bambha KM. Fatty liver: think globally. Hepatology (Baltimore, Md). 2010;51:1491-3.

[33] Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in nonoverweight individuals. Liver international : official journal of the International Association for the Study of the Liver. 2016;36:275-83.

[34] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. Journal of hepatology. 2017;67:862-73.

[35] Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics. 2008;40:1461-5.

[36] Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PloS one. 2012;7:e38322.

[37] Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatology research : the official journal of the Japan Society of Hepatology. 2017;47:1083-92.

[38] Nishioji K, Mochizuki N, Kobayashi M, Kamaguchi M, Sumida Y, Nishimura T, et al. The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain >/=10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals. PloS one. 2015;10:e0140427.

[39] Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. The Journal of pediatrics. 2011;158:740-4.

[40] Suzuki K, Akiyama M, Ishigaki K, Kanai M, Hosoe J, Shojima N, et al. Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nature genetics. 2019;51:379-86.

[41] Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nature reviews Gastroenterology & hepatology. 2017;14:32-42.

[42] Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of newonset diabetes. American heart journal. 2014;167:421-8.

[43] Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension (Dallas, Tex : 1979). 2008;51:393-8.

[44] McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England journal of medicine. 2010;362:1477-90.

[45] Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. The New England journal of medicine. 2006;355:1551-62.